A 3rd dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" enhance safety in opposition to the Delta variant -- past the safety afforded by the usual two doses, suggests new knowledge launched by Pfizer on Wednesday.
The information posted on-line, that are anticipated to be mentioned in an organization earnings name on Wednesday morning, counsel that antibody ranges in opposition to the Delta variant in folks ages 18 to 55 who obtain a 3rd dose of vaccine are higher than five-fold than following a second dose.
Amongst folks ages 65 to 85, the Pfizer knowledge counsel that antibody ranges in opposition to the Delta variant after receiving a 3rd dose of vaccine are higher than 11-fold than following a second dose.
There's "estimated potential for as much as 100-fold improve in Delta neutralization post-dose three in comparison with pre-dose three," researchers wrote within the Pfizer knowledge slides.
The information haven't but been peer-reviewed or revealed.
The information additionally present that antibody ranges are a lot larger after a 3rd dose than a second dose in opposition to the unique coronavirus variant and the Beta variant, first recognized in South Africa.
A nurse holds a vial of the Pfizer-BioNTech COVID-19 vaccine at Man's Hospital in London, on Dec. 8, 2020. (Frank Augstein / AP)
Post a Comment